CompletedNot Applicable

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

United States12 participantsStarted 2014-02

Plain-language summary

The purpose of this research study is to evaluate higher neural changes following intra-detrusor injection of Onabotulinumtoxin-A (BTX-A) in patients with Multiple Sclerosis (MS). We will use our prospectively collected cohort of patients. Concurrent Urodynamic and Functional Magnetic Resonance (fMRI) data will be recorded pre- and post-intravesical injection of BTX-A in patients with Multiple Sclerosis (MS) and neurogenic detrusor activity (NDO).

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with clinical diagnosis of neurogenic bladder. * History of any neurologic illness or injury (including but not limited to spinal cord injury, Multiple Sclerosis, spina bifida, Parkinson's, major spine surgery). * 18 years or older. * Female patients. Exclusion Criteria: * Male * History of any incontinence surgery (sling, Marshall-Marchetti-Krantz Procedure, Burch). * History of any lower urinary tract surgery or manipulation (urethral dilation). * Positive urine pregnancy test at enrollment .

What they're measuring

Change in Blood Oxygen Level Dependent (BOLD) Signals in the Brain After Treatment

Timeframe: Baseline (pre-OnabotA) and 6-10 weeks post-OnabotA treatment

Trial details

NCT IDNCT03033355

SponsorThe Methodist Hospital Research Institute

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-03

Results submitted2020-12-10

View on ClinicalTrials.gov More Multiple Sclerosis trials